Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

EU foregoes 100 million J&J vaccines, considers donating other doses: sources

Stock MarketsJun 10, 2021 05:50AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A box of Johnson & Johnson's coronavirus disease (COVID-19) vaccines is seen at the Forem vaccination centre in Pamplona, Spain, April 22, 2021. REUTERS/Vincent West/File Photo/File Photo

By Francesco Guarascio and Elvira Pollina

BRUSSELS (Reuters) - The European Union decided not to take up an option to buy 100 million doses of the Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine and is considering donating another 100 million optional shots, if ordered, European officials said.

The discussions show a drop in confidence in the one-dose shot, which was initially touted as crucial for a successful vaccination drive in Europe, but has been largely relegated to a back-up choice after safety and supply problems.

The EU at the end of March let the term to order 100 million extra doses lapse, three European officials with direct knowledge of contracts with vaccine makers told Reuters, revealing a confidential clause of the contract with J&J which had not been previously disclosed.

Under the contract, the EU ordered 200 million doses of the vaccine, and had options to buy another 200 million in two separate tranches.

The deadline for the second option for the remaining 100 million doses expires at the end of June but no decision has yet been made about whether to exercise it, the officials said.

A spokesman for the European Commission declined to comment on the matter.

The company's supply problems might play a role in the decision.

As part of the initial order, J&J committed to delivering 55 million doses to the EU by the end of June, but has so far shipped only about 12 million, according to an EU Commission official with access to the latest delivery figures.

EU governments "have voiced their concerns at the current delays", the EU spokesman said.

Two U.S.-made batches with millions of vaccines have been on hold for weeks as the European Medicines Agency (EMA) assesses their safety after cases of contaminations at a factory run by J&J subcontractor Emergent in the United States.

In another hiccup, Johnson & Johnson also briefly suspended deliveries to the EU just after it began them in April over health concerns. The vaccine has been linked to very rare but serious cases of blood clots.

J&J declined to comment on supply issues and EU's optional orders but reiterated its commitment to supplying the bloc with 200 million doses.

DONATIONS?

The EU has secured enough vaccines from other suppliers to immunize its adult population in the summer, internal estimates show, and has also a large contract with Pfizer/BioNTech for the next years, should boosters be needed.

However, the EU is still considering the possible order of optional J&J doses, mostly with the intent of donating them to poorer countries, the officials said.

The EU has so far pledged to donate at least 100 million excess doses by the end of the year.

COVAX, a vaccine programme co-led by the World Health Organization, has so far delivered only about 80 million doses to nearly 130 countries with a combined population of billions.

Before it faced supply problems, COVAX planned to ship at least 2 billion doses by the end of the year. It now relies largely on donations to meet that target.

Some of the EU's extra doses from J&J, if ordered, could be offered to COVAX, the officials said. But some EU countries may also decide to keep some for their own populations.

EU foregoes 100 million J&J vaccines, considers donating other doses: sources
 

Related Articles

S&P 500, Dow rise as economic growth picks up pace
S&P 500, Dow rise as economic growth picks up pace By Reuters - Jul 29, 2021 1

(Reuters) - The S&P 500 and the Dow indexes rose on Thursday as a slate of strong corporate earnings reports and data showing a pickup in U.S. economic growth reinforced optimism...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email